A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations

Clinical trial NCT07646821 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07646821
Sponsor: M.D. Anderson Cancer Center
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ropeginterferon Alfa-2b Azacitidine MDS/AML

Start date: 2026-11-27
Primary completion: 2028-12-11
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.